|Calculated MW||44 kDa|
|Other Names||Aldo-keto reductase family 7, member A 2, Aflatoxin B1 aldehyde reductase member 2, AFAR, AFAR1, AFB1-AR1, AKR7.|
|Sequence||MRGSHHHHHH GMASMTGGQQ MGRDLYDDDD KDRWGSELE LSAASRVVSR AAVHCALRSP PPEARALAMS RPPPPRVASV LGTMEMGRRM DAPASAAAVR AFLERGHTEL DTAFMYSDGQ SETILGGLGL GLGGGDCRVK IATKANPWDG KSLKPDSVRS QLETSLKRLQ CPQVDLFYLH APDHGTPVEE TLHACQRLHQ EGKFVELGLS NYASWEVAEI CTLCKSNGWI LPTVYQGMYN ATTRQVETEL FPCLRHFGLR FYAYNPLAGG LLTGKYKYED KDGKQPVGRF FGNSWAETYR NRFWKEHHFE AIALVEKALQ AAYGASAPSV TSAALRWMYH HSQLQGAHGD AVILGMSSLE QLEQNLAATE EGPLEPAVVD AFNQAWHLVA HECPNYFR|
|Storage||-80°C; 0.5 mg/ml solution in 20 mM Tris-HCl buffer (pH 8.0) containing 1 mM DTT and 20% glycerol.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Aldo-keto reductases, such as AKR7A2, are involved in the detoxification of aldehydes and ketones. This protein can reduce the dialdehyde protein-binding form of aflatoxin B1 (AFB1) to the nonbinding AFB1 dialcohol. It may be involved in protection of liver against the toxic and carcinogenic effects of AFB1, a potent hepatocarcinogen. Also, it has been proposed previously to catalyze the NADPH-dependent reduction of succinic semialdehyde (SSA) to Gamma-Hydroxybutyrate in human brain.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.